高盛：看好国药第4季盈利增长 维持“买入”评级
© Reuters. 高盛：看好国药(01099)第4季盈利增长 维持“买入”评级
智通财经APP获悉，高盛将国药控股 (HK:1099) 目标价由25元升至26元，维持“买入”评级。
该行指，主要受零售、毛利率改善、较低的财政支出带动，国药第3季表现胜预期。
因医院病人流动趋势、医院财政状况改善，高盛更看好第4季盈利增长的前景，并分别上调公司2020-22年每股盈利预测5.1%、1.1%、0.3%；料2020-25年每股盈利预测年复合增长率9%。不过该行也指出，公司将面对长期应收账款管理困难。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
If you like, reward to support.
Hot
No comment on record. Start new comment.